Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
Тип исследования
Тип исследования
Регистрация (Действительный)
Регистрация
Фаза
Фаза
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
Florida
-
Tampa, Florida, Соединенные Штаты, 33612
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
-
-
Texas
-
San Antonio, Texas, Соединенные Штаты, 78229
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Must have a pathologically documented advanced solid tumor that is refractory to standard treatment, for which no standard therapy is available, or for which the subject refuses standard therapy.
- Must have a tumor type that is known to express HER3. These tumors include breast, lung, prostate, ovarian, cervical, endometrial, gastric, pancreatic, bladder, head and neck, liver, colon, and esophageal cancer. Other tumors will be considered based on emerging HER3 expression data.
- Must be competent and able to comprehend, sign, and date an IRB-approved ICF (including HIPAA authorization, if applicable) before performance of any study-specific procedures or tests.
- Must have an ECOG performance status of ≤ 2
Women must be one of the following:
- Postmenopausal (having had no menstrual period for a minimum of 12 months) or surgically sterile, or
- If of childbearing potential, must have been willing to use maximally effective birth control during the period of therapy and use contraception for 6 months following the last investigational drug infusion and must have had a negative urine or serum pregnancy test upon entry into the study.
- Men must be surgically sterile or willing to use a double-barrier contraception method upon enrollment, during the course of the study, and for 6 months following the last investigational drug infusion.
Have hematological function, as follows:6. Men
- Absolute neutrophil count of ≥ 1.5 × 109/L
- Platelet count ≥ 100 × 109/L
- Hemoglobin ≥ 9 g/dL
Have renal function, as follows:
- Calculated creatinine clearance rate (CrCl) ≥ 60 mL/minute using the modified Cockcroft-Gault equation or serum creatinine ≤ 1.5 × ULN.
Have hepatic function, as follows:
- AST ≤ 2.5 × ULN (if liver metastases are present, < 5 × ULN)
- ALT ≤ 2.5 × ULN (if liver metastases are present, < 5 × ULN)
- Alkaline phosphatase ≤ 2.5 × ULN (if bone or liver metastases are present, < 5 × ULN)
- Bilirubin ≤ 1.5 × ULN
- Prothrombin time (PT) or partial thromboplastin time (PTT) ≤ 1.5 × ULN
Exclusion Criteria:
- Have a history of lymphoma, leukemia, or other hematopoietic malignancy.
- Have Have autologous or allogeneic stem cell transplant.
- Have any comorbid medical condition that would increase the risk of toxicity in the opinion of the investigator or sponsor.
- Have untreated or symptomatic brain metastasis.
- Have unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE Version 4.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia. Subjects with irreversible Grade 2 toxicity may be eligible as per discretion of the investigator and sponsor (e.g., Grade 2 chemotherapy-induced neuropathy).
- Have uncontrolled hypertension (diastolic blood pressure > 100 mmHg or systolic blood pressure > 140 mmHg). It is permissible for the subject to receive treatment with antihypertensive medication to maintain blood pressure within the required parameters.
- Have clinically significant ECG changes that obscure the ability to assess the RR, PR, QT, QT interval corrected for heart rate (QTc), and QRS interval. Subjects with left bundle branch block, atrial fibrillation and use of cardiac pacemaker specifically will be excluded.
- Have ascites or pleural effusion requiring chronic medical intervention.
- Have a history of bleeding diathesis.
- Have had a myocardial infarction within 1 year before enrollment, symptomatic CHF (New York Heart Association > Class II;), unstable angina, or unstable cardiac arrhythmia requiring medication.
- Use of amiodarone within 6 months prior to enrollment.
- Concurrent use of antiarrhythmic medications with the exception of beta blockers for treatment of hypertension.
- Subjects who are receiving drugs that may affect QTc (e.g., quinidine or moxifloxacin).
- QTc interval > 450 msec on the average of the triplicate readings by Friderica's formula on 2 successive screening measurements (second measurement is required if first measurement is > 450 msec).
- Have a LVEF < 50%.
- Have anthracycline exposure greater than 360 mg/m2.
- Have a history of chronic hepatitis or known active infection with hepatitis B virus or hepatitis C virus.
- Personal or family history of long-QT syndrome.
- Have known infection with or a history of testing positive for human immunodeficiency virus (HIV).
- Had treatment with anticancer therapy (6 weeks for nitrosoureas and mitomycin C chemotherapies and 2 weeks for small molecule tyrosine kinase inhibitors), antibody therapy, retinoid therapy, or hormonal therapy within 4 weeks before study Day 1. Prior and concurrent use of hormone replacement therapy or the use of gonadotropin releasing hormone modulators for prostate cancer is permitted.
- Had therapeutic or palliative radiation therapy within 4 weeks before enrollment (in addition, he/she must have had resolution of any significant AEs from radiation therapy at least 2 weeks before enrollment).
- Have concurrent or previous (within 1 week of study Day 1) anticoagulation therapy, except low-dose warfarin (≤ 2 mg/day) or low-dose, low-molecular weight heparin for prophylaxis against central venous catheter thrombosis or deep vein thrombosis.
- Have participated in clinical drug trials within 4 weeks before enrollment.
- Have had major surgery within 4 weeks before enrollment.
- Is currently participating in other investigational procedures.
- Has any disorder that compromised the ability of the subject to give written informed consent and/or comply with study procedures.
- Has known sensitivity to any of the products to be administered during dosing or known allergy to the excipients or investigational drugs.
- Has active infection within 2 weeks before enrollment unless there was a discussion with the sponsor and an agreement was reached that the recent infection would not affect the subject's participation in the study.
- Has previously received an anti-HER3 targeted antibody, including patritumab.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Process 2 patritumab
Process 2 patritumab 18 mg/kg (loading dose) on Day 1 of Cycle 1 followed by Process 2 patritumab 9 mg/kg (maintenance dose) once every 21 days starting on Day 1 of Cycle 2 through Cycle 5.
|
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
AUC (0-21 day) of Patritumab
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
AUC (0-21 day) of patritumab obtained after a single infusion of Process 2 patritumab 18 mg/kg (loading dose)
|
5 Cycles, each of which lasts 21 Days
|
|
Cmax of Patritumab
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
Cmax of patritumab obtained after a single infusion of Process 2 patritumab 18 mg/kg (loading dose)
|
5 Cycles, each of which lasts 21 Days
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
volume of distribution [Vz]
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters volume of distribution [Vz]
|
5 Cycles, each of which lasts 21 Days
|
|
Safety and Tolerability of Process 2 patritumab - (electrocardiograms [ECG)
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the safety and tolerability of Process 2 patritumab (electrocardiograms [ECG)
|
5 Cycles, each of which lasts 21 Days
|
|
Antibody Formation
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To characterize the formation of antibodies to patritumab human antihuman antibodies (HAHA) after infusion of Process 2 patritumab
|
5 Cycles, each of which lasts 21 Days
|
|
Concentration patritumab at 504 hours
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameter concentration of patritumab at 504h [C504]
|
5 Cycles, each of which lasts 21 Days
|
|
AUC to infinity [AUC0-inf]
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters AUC to infinity [AUC0-inf]
|
5 Cycles, each of which lasts 21 Days
|
|
time to Cmax (Tmax)
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters time to Cmax (Tmax)
|
5 Cycles, each of which lasts 21 Days
|
|
concentration at the end of infusion (Ceoi)
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters concentration at the end of infusion (Ceoi)
|
5 Cycles, each of which lasts 21 Days
|
|
terminal elimination half-life (t 1/2)
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters terminal elimination half-life (t 1/2)
|
5 Cycles, each of which lasts 21 Days
|
|
clearance (CL)
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters clearance (CL)
|
5 Cycles, each of which lasts 21 Days
|
|
trough concentration (Ctrough)
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters trough concentration (Ctrough)
|
5 Cycles, each of which lasts 21 Days
|
|
echocardiograms/multi-gated acquisition [MUGA] scans of Process 2 patritumab
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the safety and tolerability of Process 2 patritumab echocardiograms/multi-gated acquisition [MUGA] scans
|
5 Cycles, each of which lasts 21 Days
|
|
adverse events [AEs] of Process 2 patritumab
Временное ограничение: 5 Cycles, each of which lasts 21 Days
|
To assess the safety and tolerability of Process 2 patritumab adverse events [AEs] of Process 2 patritumab
|
5 Cycles, each of which lasts 21 Days
|
Соавторы и исследователи
Спонсор
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования
Начало исследования
Первичное завершение (Действительный)
Первичное завершение
Завершение исследования (Действительный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- U31287-A-U105
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .